Paclitaxel (Taxol) is a potent anti-neoplastic and anti-mitotic taxane compound used in cancer chemotherapy. Paclitaxel binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division. The ability of paclitaxel to inhibit spindle function is generally attributed to its suppression of microtubule dynamics, but recent studies have demonstrated that suppression of dynamics occurs at concentrations lower than those needed to block mitosis. At the higher therapeutic concentrations, paclitaxel appears to suppress microtubule detachment from centrosomes, a process normally activated during mitosis. The binding site for paclitaxel has been identified on the beta-tubulin subunit. In vitro and in vivo studies have demonstrated that paclitaxel is extensively metabolised by the liver to 3 primary metabolites.
Drug Deliv. 2021 Dec;28(1):2256-2267.
GLUT1 targeting and hypoxia-activating polymer-drug conjugate-based micelle for tumor chemo-thermal therapy
Paclitaxel purchased from AbMole
Transl Lung Cancer Res. 2021 Feb;10(2):1007-1019.
Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/β-catenin signaling pathway in taxol-resistant human lung adenocarcinoma
Paclitaxel purchased from AbMole
Chem Pharm Bull (Tokyo). 2021;69(4):325-332.
MiR-509-3p Induces Apoptosis and Affects the Chemosensitivity of Cervical Cancer Cells by Targeting the RAC1/PAK1/LIMK1/Cofilin Pathway
Paclitaxel purchased from AbMole
Oncogene. 2020 Sep;39(37):6024-6040.
CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK
Paclitaxel purchased from AbMole
Cell Cycle. 2018;17(10):1235-1244.
Apatinib, a novel tyrosine kinase inhibitor, suppresses tumor growth in cervical cancer and synergizes with Paclitaxel.
Paclitaxel purchased from AbMole
Cancer Biol Ther. 2018 Feb 5.
Buformin suppresses proliferation and invasion via AMPK/S6 pathway in cervical cancer and synergizes with paclitaxel
Paclitaxel purchased from AbMole
Cell Experiment | |
---|---|
Cell lines | human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs |
Preparation method | Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well. |
Concentrations | 0.1-100 pM |
Incubation time | 72 h |
Animal Experiment | |
---|---|
Animal models | nude athymic mice with BC-V and BC-ER tumors |
Formulation | Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use |
Dosages | 20 mg/kg |
Administration | i.v. |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Molecular Weight | 853.91 |
Formula | C47H51NO14 |
CAS Number | 33069-62-4 |
Purity | 99.33% |
Solubility | DMSO 50 mg/mL |
Storage | -20°C, sealed, protect from light |
[3] Sonnichsen DS, et al. Clin Pharmacokinet. Clinical pharmacokinetics of paclitaxel.
Related Microtubule Products |
---|
Colcemid
Colcemid (Demecolcine) is an effective mitotic inhibitor. Colcemid binds tubulin and blocks cells for metaphase karyotype analysis. Colcemid can induce apoptosis and can be used in tumor research. |
sabizabulin
VERU-111 (ABI-231) is a highly potent, orally available α/β tubulin inhibitor with strong antiproliferative activity and an average IC for action on melanoma and prostate cancer cell lines50 The value is 5.2 nM. |
BNC105
BNC105 IS A TUBULIN POLYMERIZATION INHIBITOR THAT IS RESISTANT TO PROLIFERATION AND DESTRUCTION OF TUMOR VASCULAR FUNCTION. |
Verubulin
Verubulin (MPC-6827) is a highly effective, broad-spectrum microtubule blocker with in vivo and in vitro cytotoxic activity, promising as a potential drug candidate for a wide range of cancers. |
Batabulin sodium
Batabulin (T138067) sodium is a synthetic pentafluorophenylsulfonamide with potential antineoplastic activity, covalently binds to and selectively modifies the beta 1, beta 2, beta 3, and beta 4 isotypes of beta tubulin at a conserved cysteine residue, resulting in disruption of microtubule polymerization, collapse of the cytoskeleton, an increase in chromosomal ploidy, cell cycle arrest, and tumor cell apoptosis. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.